TMEM255A

Across TCGA pan-cancer cohorts, TMEM255A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM255A data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TMEM255A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM255A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, UCEC, and COAD are the cancer types where TMEM255A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.183	0.660	.009	18	view →
UCEC	DFS	Median	II,III,IV	0.933	0.479	.021	16	view →
COAD	DFS	Median	All	0.237	0.699	.004	7	view →
HNSC	OS	Median	All	0.191	0.710	.021	6	view →
SKCM	DFS	Median	II,III,IV	0.276	0.715	.005	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM255A–STAD (OS)

Open the STAD breakdown →